In LNCaP cells, 10µM Amiloride individually reduced cell viability by 63.2%. Treatment with 10µM Amiloride for 72 h also produced a slight decrease in early apoptosis. In human sperm undergoing a switch from pHo 6.5 to pHo 7.7 with human serum albumin at 3 mg/ml, comparison in the absence and presence of Amiloride showed that 500 μM completely prevented alkalization. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Amiloride and LNCaP cell viability
Cell-based study · LNCaP cells [1]
In LNCaP cells, 10µM Amiloride individually reduced cell viability by 63.2%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10µM
- Vehicle
- 100% DMSO
- Reported limits
- Not stated in the sentences used: route, schedule.
Methods and source locations
Compound reported in the paper: Amiloride
Evidence for Amiloride as the hydrochloride form reported in the paper, not the dihydrate, hydrochloride form supplied as A11728; no salt equivalence, dose conversion or lot validation.
Materials and methods > 3-[4,5-Dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium bromide assay (S20); Materials and methods > Statistical analysis (S48); Results > Amiloride enhances the sensitivity of HSPC cells to lapatinib (S120, S121, S122); Fig. 5 legend (S198, S199)
cell viability: cell viability; comparator: DMSO — Results > Amiloride enhances the sensitivity of HSPC cells to lapatinib (S122); Fig. 5 legend (S199)
Amiloride and alkalization in human sperm
Cell-based study · human sperm [2]
Human sperm were examined during a switch from pHo 6.5 to pHo 7.7, with human serum albumin present at 3 mg/ml. Comparison in the absence and presence of Amiloride isolated its effect: 500 μM completely prevented alkalization.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 μM
- Method
- continuous flow of perfusion
- Co-treatment
- Other interventions in this design: a switch from pHo 6.5 to pHo 7.7; human serum albumin (HSA) 3 mg/ml. Compound effect isolated by the comparison: absence and presence of amiloride.
- Reported limits
- Not stated in the sentences used: schedule, vehicle.
Methods and source locations
Compound reported in the paper: Amiloride
The paper names Amiloride without stating the salt or form; not verified as the dihydrate, hydrochloride form supplied as A11728. No dose conversion or lot validation.
Methods > Sperm preparation (S14); Methods > Solutions for electrophysiological and fluorometric recordings (S90); Methods > Fluorometry (S117); Methods > Analysis of fluorometric and electrophysiologic data (S149); Fig. 3 legend (S174, S175)
Changes in pHi upon a switch from pHo 6.5 to pHo 7.7: Changes in pHi upon a switch from pHo 6.5 to pHo 7.7; comparator: absence and presence of amiloride — Fig. 3 legend (S174, S175)
Amiloride and early apoptosis in LNCaP cells
Cell-based study · LNCaP cells [1]
In LNCaP cells treated with 10µM Amiloride for 72 h, early apoptosis showed a slight decrease.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10µM
- Exposure duration
- 72 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Amiloride
Evidence for Amiloride as the hydrochloride form reported in the paper, not the dihydrate, hydrochloride form supplied as A11728; no salt equivalence, dose conversion or lot validation.
Materials and methods > Flow cytometry for apoptosis (S26); Results > Low dose amiloride and lapatinib combine to induce apoptosis in HSPC cells (S155, S156); Fig. 7 legend (S243, S244)
early apoptosis: early apoptosis; comparator: 100% DMSO — Results > Low dose amiloride and lapatinib combine to induce apoptosis in HSPC cells (S156)